Comparative Pharmacology
Head-to-head clinical analysis: MIGERGOT versus WIGRAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIGERGOT versus WIGRAINE.
MIGERGOT vs WIGRAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergotamine is a partial agonist at serotonin (5-HT) receptors, particularly 5-HT1B/1D, and also exhibits agonism at alpha-adrenergic and dopamine receptors. It causes vasoconstriction of cranial blood vessels and reduces central pain transmission.
WIGRAINE is a combination product containing ergotamine, a vasoconstrictor that acts as an agonist at serotonin (5-HT1B/1D) and alpha-adrenergic receptors, and caffeine, which enhances ergotamine absorption and provides additional vasoconstriction.
1 mg ergotamine tartrate and 100 mg caffeine per rectal suppository, inserted rectally at onset of headache; may repeat after 1 hour if needed, maximum 2 suppositories per headache and 5 per week.
For acute migraine: 2 tablets (each containing ergotamine tartrate 1 mg and caffeine 100 mg) orally at onset, then 1 tablet every 30 minutes as needed, maximum 6 tablets per attack, maximum 10 tablets per week.
None Documented
None Documented
Ergotamine: 2 hours (initial) with terminal half-life 21-34 hours due to enterohepatic recirculation; caffeine: 3-6 hours.
Ergotamine: ~2-3 hours (terminal). Clinical context: short half-life necessitates frequent dosing for acute migraine relief.
Primarily hepatic metabolism (ergotamine) with 90% biliary/fecal elimination as metabolites; less than 4% renal excretion unchanged.
Primarily hepatic metabolism; renal excretion of metabolites. ~90% urinary, ~10% fecal.
Category C
Category C
Ergot Alkaloid
Ergot Alkaloid